Whalegun
Lobbying

DR. Reddy's Laboratories RDY's latest lobbying report covers Q2 2026, at $60K. The four quarters Q4 2025–Q3 2026 total $180K. Its first report covers Q4 2022; the issues it reports most are Pharmacy.

DR. Reddy's LaboratoriesRDY

DR. Reddy's Laboratories stock page

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$180K
Last 4 quarters
vs last quarter
−100.0%
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

DR. Reddy's Laboratories lobbying by quarter
DR. Reddy's Laboratories lobbying by quarter
QuarterAmountReports
Q4 2022$60K1
Q1 2023$60K1
Q2 2023$60K1
Q3 2023$60K1
Q4 2023$60K1
Q1 2024$60K1
Q2 2024$60K1
Q3 2024$60K1
Q4 2024$60K1
Q1 2025$60K1
Q2 2025$60K1
Q3 2025$60K1
Q4 2025$60K1
Q1 2026$60K1
Q2 2026$60K1
Q3 2026$00

By issue

  • Pharmacy$900K · 15 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • Drug Enforcement Administration (DEA)15 reports
  • HOUSE OF REPRESENTATIVES15 reports
  • Natl Institutes of Health (NIH)15 reports
  • SENATE15 reports
  • Food & Drug Administration (FDA)1 reports

Firms it paid

Firm
Rubicon Advisors$900K15 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
07/20for Q2Rubicon Advisors$60K
04/23for Q1Rubicon Advisors$60K
01/18for Q4 2025Rubicon Advisors$60K
25/10/21for Q3 2025Rubicon Advisors$60K
25/07/19for Q2 2025Rubicon Advisors$60K
25/04/21for Q1 2025Rubicon Advisors$60K
25/01/21for Q4 2024Rubicon Advisors$60K
24/10/22for Q3 2024Rubicon Advisors$60K
24/07/17for Q2 2024Rubicon Advisors$60K
24/05/08for Q1 2024Rubicon Advisors$60K
24/01/25for Q4 2023Rubicon Advisors$60K
23/10/22for Q3 2023Rubicon Advisors$60K
23/07/23for Q2 2023Rubicon Advisors$60K
23/04/20for Q1 2023Rubicon Advisors$60K
23/01/16for Q4 2022Rubicon Advisors$60K